Review

The developments in paradigm of prostate cancer in recent years

• Sertaç Yazıcı
• Halil Kızılöz
• Haluk Özen

Prognostic factors in renal cancer and prediction models

• Ümit Gül
• Özgür Yaycıoğlu

Mesane kanseri; Karsinoma İn Situ (CIS)

• Polat Türker
• Sinan Ekici

Complications of Urinary Diversions and their Treatment

• Eyüp Gümüs
• Ugur Boylu

BCG suşlarının tedavi edici etkinlik farkı var mı?

• Hayrettin Şahin

Treatment of small renal masses: Where we are in 2011

• Mutlu Ateş
• Mustafa Karalar
• Engin Doğantekin

Is intravesical BCG treatment necessary and/or sufficient?

• Sinan Ekici
• Polat Türker

Does the Future of Prostate Cancer Treatment Lie with Apoptotic Inducers?

• Dr. Ece Konaç
• Dr. Sinan Sözen

Benign Prostatic Hyperplasia: not recomended in diagnosis and treatment (Implented with in the historical process, but right now that is not recommended and not recommended guidelines)

• Şakir Ongün
• İlhan Çelebi

Endoscopic treatment of BPH

• Ünal Sert
• Özcan Kılıç

Re-operation rates and possible causes related to minimally invasive and surgical treatments of Benign Prostatic Hyperplasia

• Serdar Toksöz
• Hakan Özkardeş

Importance of mycobacteria in treatment of bladder tumor

• Esra Büber
• Selçuk Keskin
• N. Leyla Açan

Active Surveillance: Treatment Modality that Expect Attention for Localized Prostate Cancer

• Tayyar Alp Özkan
• Özdal Dillioğlugil

Supportive treatment for patient receiving gemsitabine-cisplatine and suggestions for nursing

• Yeter Kırdal

Is it possible to predict BCG effectivity in the treatment of superficial bladder cancer? Are there any markers?

• Polat Türker
• Sinan Ekici

A critical analysis of surgical curative treatments options in localised prostate cancer: open, laparoscopic, and robotassisted radical prostatectomy

• Ender Özden
• Yakup Bostancı
• Yarkın Kamil Yakupoğlu

The role of 5α-reductase inhibitors on prevention and hormonal treatment of prostate cancer

• Bülent Öztürk
• Tufan Çiçek

Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup

• Yılören Tanıdır
• İlker Tınay

Algorithmic approach to rising PSA after curative prostate cancer treatment

• Levent Mert Günay
• Şevket Tolga Tombul
• Bülent Akdoğan

Is TUR-B operations can be done in the office conditions by using local anesthesia

• Tansu Değirmenci
• Bülent Günlüsoy

Are radiological imagings useful in diagnosis, treatment and follow-up of Benign Prostatic Hyperplasia?

• Umut Gönülalan
• Bülent Öztürk

Outstanding variations in the treatment of prostate cancer bone metastases

• İbrahim Cüreklibatır

Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer

• Erem Bilensoy
• Nazlı Erdoğar
• Aydın N. Mungan

Neoadjuvant and adjuvant treatment modalities for prostate cancer

• Erkan Erkan
• Gökhan Toktaş

The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer

• Bertrand Tombal

A New Era in Metastatic Prostate Cancer: “The Combination of Chemotherapy and Hormonal Treatment as Initial Treatment”

• İlker Tinay
• Levent Türkeri

Targeted Therapies in Metastatic Bladder Cancer: Has It Been Approved as a Treatment Option Nowadays?

• Nil Molinas Mandel

What is the evidence-based ideal treatment of clinical locally advanced (cT3) prostate cancer?

• Asıf Yıldırım
• Erem Kaan Başok

Hormonal treatment of metastatic prostate cancer: Today and future

• Hasan Soydan
• Kadir Baykal

Treatment options in low-intermediate risk prostate cancer

• Saadettin Yılmaz Eskiçorapçı
• Deniz Bolat

Robotic assisted laparoscopic surgery for the treatment of kidney cancer:current status in 2011

• Cihan Toktaş
• Saadettin Eskiçorapçı

Are there any treatment option for metastatic prostate cancer refractory to docetaksel?

• Yaşar Bedük

Which Treatment Should We Prefer for High-Risk Nonmuscle Invasive Bladder Cancer? Early Cystectomy or Bladder Sparing?

• Ali Furkan Batur
• Sinan Sözen

Surgical treatment and/or radiotherapy in high risk prostate cancer

• Fatih Bıçaklıoğlu
• Cenk Acar
• Sinan Sözen

Is Lymphadenectomy Necessary in the Surgical Treatment of Upper Urinary Tract Urothelial Carcinoma?

• Yakup Kordan
• Onur Kaygısız

The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?

• Polat Türker
• Levent Türkeri

New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor

• Yavuz Selim Süral
• Çağ Çal

New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate

• Bülent Akdoğan

Radical Prostatectomy and Lymphadenectomy in the High-Risk Prostate Cancer: Surgical Technique, Functional and Oncologic Outcomes

• Hayrettin Şahin
• Hasan Deliktaş

New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T

• Gürbüz Görümlü
• Erdem Göker

New treatment options in castration resistant prostate cancer: denosumab, alpharadin

• Hakan Gemalmaz

The Prostatic Urethral Lift Method: A New Minimally Invasive Modality as an Alternative in the Treatment of Benign Prostatic Hyperplasia

• Alpaslan Yüksel
• Ali Tekin

Treatment Approaches for Nonmetastatic Castration-Resistant Prostate Cancer

• Mehmet Yıldızhan
• Hakan Gemalmaz
• Mehmet Şirin Ertek

Current Status of Laparoscopic Radical Nephroureterectomy in the Treatment Modalities for Upper Urinary Tract Tumors

• Ahmet Güdeloğlu
• Cenk Yücel Bilen

How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?

• İlker Çelen
• Murat Lekili

Active Surveillance in Prostate Cancer

• Volkan İzol
• Nebil Akdoğan

Current treatment approaches in locally advanced prostate cancer: a radiation oncologist perspective

• Ömür Karakoyun Çelik

Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer

• Hayrettin Şahin
• Hasan Deliktaş

Management of recurrences after radiation therapy used for curative intent in prostate cancer

• Yılören Tanıdır
• Levent Türkeri

Prostate cancer in the era of robotic surgery

• Çag Çal

‘Nanotechnology Applications’ in the Treatment of Prostate Cancer

• Ali Furkan Batur
• Kerem Gencer Kutman
• Mustafa Suat Bolat

Current Treatment of Testicular Sex Cord-Stromal Tumors

• Şahin Kabay
• Mithat Ekici

Immunotherapy for the treatment of castration resistant prostate cancer: sipuleucel-T

• Güven Aslan

Active Surveillance-Factors Affecting the Treatment Decision: 3M: “Marker”, “Mapping”, “MRI”

• Ender Özden
• Mehmet Necmettin Mercimek

New treatment stragies in metastatic castration resistant prostate cancer: Re-Docetaxel, Abiraterone asetate, Cabazitaxel, MDV 3100

• Sıtkı Ün
• Ferruh Zorlu

Surgical Approach to the Patients with Positive Surgical Margin after Nephron Sparing Surgery

• Bülent Günlüsoy
• Yasin Ceylan
• Tansu Değirmenci

Current situation of the clinical stage I nonseminomatous germ cell testis tumour

• Alim Koşar
• Osman Ergün

Molecular Fundamentals of the Revolution in the Treatment of Renal Cell Carcinoma

• Ece Konaç
• Sinan Sözen

Follow-up principles after curative treatment in renal cancer

• Ercan Kazan
• Hakan Gemalmaz

Liquid Biopsy: Circulating Tumor Cells and its Impact on Follow-up/Treatment of Prostate Cancer Patients

• İbrahim Kulaç

The Diagnosis and Treatment of Retroperitoneal Mass

• Ümit Gül

Interventional Treatment of Benign Prostatic Hyperplasia on Elderly People: Prostatic Stent and Prostatic Arterial Embolization

• Eray Hasırcı
• Mehmet İlteriş Tekin

Active surveillence in small kidney tumors

• Yasin Ceylan
• Bülent Günlüsoy

Cytoreductive Nephrectomy in the Targeted Treatment Era

• Özgür Yaycioglu

Should the treatment approach be different for incidental renal tumors? Turkey databases

• Emre Huri

Management of Upper Urinary Tract Tumors: Comparative Oncological Evaluation of Radical Nephroureterectomy and Nephron Sparing Endoscopic Treatments

• Ali Tekin
• Alpaslan Yüksel

Open partial nephrectomy: recent situation

• İyimser Üre
• Sinan Sözen

Molecular Biology in Diagnosis and Treatment of Prostate Cancer

• Ece Konaç
• Sinan Sözen

The Treatment Modalities in Stage 1 Seminoma; Alterations in Last Five Years

• Baris Kuzgunbay

Could We Reach the Standard Treatment of Lower Urinary Tract Symptoms/Benign Prostate Hyperplasia?

• Eray Hasırcı
• Murat Koşan

Minimally invasive treatments for upper urinary tract transitional epithelial carcinoma

• Mehmet Selçuk Keskin

Diagnostic and Prognostic Molecular Features of Urothelial Bladder Cancer and New Treatment Approaches

• Zafer Küçükodacı
• Kutsal Yörükoğlu

Surgical Treatment Options for High Risk Patients with Benign Prostatic Hyperplasia

• Eray Hasırcı
• Ayhan Dirim
• Hakan Özkardeş

The Role of Enflammation as an Etiopathogenetic Mechanism and Treatment Target in Benign Prostatic Hyperplasia

• Ali Tekin
• Alpaslan Yüksel

The Effects of Medical Treatments Used for Benign Prostatic Hyperplasia on Ejaculation

• Ali Kayıkçı
• Coşkun Kaçağan
• Ali Tekin

Alpha Blocker Treatment and Intra-operative Floppy Iris Syndrome

• Mehmet Emin Özyalvaçlı
• Ümit Doğan
• Adnan Gücük

Quality of Life of Patients with Advanced/Metastatic Renal Cell Carcinoma During the Treatment Period with Targeted Drugs

• Sinharib Çitgez

Article - Comment

Treatment delay and prognosis in invasive bladder cancer

• Sertaç Yazici

Treatment of testicular cancer: Influence on pituitary-gonadal axis and sexual function

• Ali Ihsan Arik

Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

• Ali Tekin

Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794

• Sefik Igdem

Laparoscopic versus open partial nephrectomy for the treatment of pathological T1N0M0 renal cell carcinoma: a 5-year survival rate

• Yildirim Bayazit

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy—a propensity scoring approach

• Cemil Uygur

Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer

• Recep Büyükalpelli

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

• Ali F. Şahin

Quality Of Life

Association of the Benign Prostatic Hyperplasia and erectile dysfunction, the current treatment modalities in Benign Prostatic Hyperplasia

• Volkan Şen
• Ömer Demir
• Ahmet Adil Esen

Male lower urinary tract symptoms: An update – overactive bladder or not ?

• Tufan Tarcan
• İlker Tınay

Causes and treatment of postprostatectomy incontinence

• Bedreddin Seçkin
• Özcan Kılıç

BPH: The actual case and the future

• Cüneyt İşeri

Can we prevent erectile dysfunction following radical prostatectomy? What are the medical and surgical alternatives?

• Cem Akbal
• Ferruh Şimsek

The comparison of the treatment alternatives on quality of life in testicular cancers

• Sinharib Çitgez
• Çetin Demirdağ
• Kamil Çam

Radiation Oncology

Radiation therapy for bladder cancer

• Ömür Karakoyun Çelik
• Fatma Sert

Bph

Prostatic inflammation as a target of etiopathogenesis and treatment

• Murat Koşan
• Umut Gönülalan

Will lasers replace transurethral resection of the prostate for the treatment of BPH?

• Ali Erol
• Serhat Dönmezer
• Erem Kaan Başok

How can LUTS can be treated in BPH patients with high morbidity?

• Uğur Yücetaş
• Gökhan Tokdaş

Long-term treatment of Benign Prostatic Hyperplasia with the combination of alpha blockers and 5-alpha reductase inhibitors

• Cevahir Özer
• Mehmet İlteriş Tekin

Monopolar and bipolar transurethral prostate resection in surgical treatment of benign prostatic hyperplasia

• Eray Hasırcı
• Ayhan Dirim

Antimuscarinics in the treatment of overactive bladder: does one fit all? Can treatment be individualized?

• Ceyhun Özyurt